GlassScriptPhysician profile
Anil K Sharma
NPI 1760466254
$5,162.94
in general payments reported to CMS, 2019-2025
30 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $343 · 2021: $631 · 2022: $937 · 2023: $690 · 2024: $937 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,249.14 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Abbvie INC. | $977.71 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $434.51 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.51 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Ferring Pharmaceuticals INC. | $250.50 | 2021-2025 | Rebyota |
| Pfizer INC. | $237.36 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $135.18 | 2022-2025 | Dupixent |
| Ucb, INC. | $134.26 | 2019 | |
| Celgene Corporation | $119.35 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $117.90 | 2019-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $111.99 | 2019-2024 | |
| Qol Medical, LLC | $111.61 | 2019-2022 | |
| Gilead Sciences, INC. | $96.22 | 2019-2025 | |
| Exact Sciences Corporation | $90.95 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $88.52 | 2025 | Zenpep, Vowst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $74.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $64.22 | 2019-2021 | |
| Novo Nordisk INC | $56.80 | 2023-2025 | Wegovy |
| Amgen INC. | $56.70 | 2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $51.09 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $47.00 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $42.35 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $40.61 | 2025 | Rezdiffra |
| Organon LLC | $36.63 | 2024 | |
| Phathom Pharmaceuticals, INC. | $30.19 | 2024 | Voquezna |
| Concordia Pharmaceuticals INC. | $24.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2023 | Cyltezo |
| Lilly USA, LLC | $17.39 | 2025 | Omvoh |
| Aries Pharmaceuticals, INC. | $15.09 | 2019 | |
| Allergan, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.